EA202090471A1 - Модулирующие т-клетки мультимерные полипептиды и способы их применения - Google Patents
Модулирующие т-клетки мультимерные полипептиды и способы их примененияInfo
- Publication number
- EA202090471A1 EA202090471A1 EA202090471A EA202090471A EA202090471A1 EA 202090471 A1 EA202090471 A1 EA 202090471A1 EA 202090471 A EA202090471 A EA 202090471A EA 202090471 A EA202090471 A EA 202090471A EA 202090471 A1 EA202090471 A1 EA 202090471A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- modulating
- polypeptides
- ways
- dimensional
- application
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 4
- 230000000694 effects Effects 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762555499P | 2017-09-07 | 2017-09-07 | |
| PCT/US2018/049756 WO2019051091A1 (en) | 2017-09-07 | 2018-09-06 | T-LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202090471A1 true EA202090471A1 (ru) | 2020-06-10 |
Family
ID=65634643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202090471A EA202090471A1 (ru) | 2017-09-07 | 2018-09-06 | Модулирующие т-клетки мультимерные полипептиды и способы их применения |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20200148744A1 (enExample) |
| EP (1) | EP3678691A4 (enExample) |
| JP (1) | JP2020533273A (enExample) |
| KR (1) | KR20200040860A (enExample) |
| CN (1) | CN111050793A (enExample) |
| AU (1) | AU2018328280B2 (enExample) |
| BR (1) | BR112020004535A2 (enExample) |
| CA (1) | CA3070484A1 (enExample) |
| EA (1) | EA202090471A1 (enExample) |
| IL (2) | IL297361B2 (enExample) |
| MX (1) | MX2020002596A (enExample) |
| TW (1) | TW201920248A (enExample) |
| WO (1) | WO2019051091A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109475628A (zh) * | 2016-05-18 | 2019-03-15 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| AU2017379900B2 (en) | 2016-12-22 | 2024-12-05 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| WO2018129474A1 (en) | 2017-01-09 | 2018-07-12 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| EP3596118B1 (en) | 2017-03-15 | 2024-08-21 | Cue Biopharma, Inc. | Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer |
| JP7165717B2 (ja) | 2017-03-15 | 2022-11-04 | パンディオン・オペレーションズ・インコーポレイテッド | 標的免疫寛容 |
| MX2019013517A (es) | 2017-05-24 | 2020-08-17 | Pandion Operations Inc | Inmunotolerancia dirigida. |
| WO2019051127A1 (en) * | 2017-09-07 | 2019-03-14 | Cue Biopharma, Inc. | MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| TWI856047B (zh) * | 2018-12-19 | 2024-09-21 | 美商信號生物製藥公司 | 多聚體t細胞調節多肽及其使用方法 |
| EP3719033A1 (en) | 2019-04-02 | 2020-10-07 | imusyn GmbH & Co. KG | Stabilized mhc i |
| EP3972992A4 (en) | 2019-05-20 | 2023-07-19 | Pandion Operations, Inc. | MADCAM TARGETED IMMUNOTLERANCE |
| EP3986448A4 (en) * | 2019-06-19 | 2023-07-12 | Cue Biopharma, Inc. | MULTIMERIC T-CELL-MODULATING POLYPEPTIDES AND METHODS OF USE THEREOF |
| TW202128961A (zh) | 2019-11-20 | 2021-08-01 | 美商安維塔生物科學股份有限公司 | 細胞激素融合蛋白及其醫藥組合物及治療應用 |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| EP4140495A4 (en) * | 2020-03-18 | 2024-05-01 | GI Innovation, Inc. | Pharmaceutical composition for cancer treatment comprising fusion protein including il-2 protein and cd80 protein and anticancer drug |
| US11897930B2 (en) | 2020-04-28 | 2024-02-13 | Anwita Biosciences, Inc. | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications |
| CN111592580A (zh) * | 2020-05-08 | 2020-08-28 | 中国药科大学 | 一种具有免疫检查点ctla-4抑制活性的多肽及其应用 |
| EP4149534A4 (en) | 2020-05-12 | 2024-09-04 | Cue Biopharma, Inc. | MULTIMERIC POLYPEPTIDES MODULATING T CELLS AND METHODS OF USE THEREOF |
| JP2023525822A (ja) * | 2020-05-12 | 2023-06-19 | エルジー・ケム・リミテッド | 多量体t細胞調節性ポリペプチド及びその使用方法 |
| WO2022015880A2 (en) * | 2020-07-14 | 2022-01-20 | Cue Biopharma, Inc. | T-cell modulatory polypeptides with conjugation sites and methods of use thereof |
| WO2022056014A1 (en) | 2020-09-09 | 2022-03-17 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof |
| CN113424794B (zh) * | 2021-04-16 | 2022-07-26 | 安徽农业大学 | 一种优质抗病型地方鸡新品系选育方法 |
| CN119110731A (zh) * | 2022-03-01 | 2024-12-10 | 交联治疗公司 | 作为抗癌剂的免疫细胞功能的atp依赖性激动剂 |
| WO2024231535A1 (en) * | 2023-05-11 | 2024-11-14 | Immudex Aps | Mhc class i molecules |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030007978A1 (en) * | 1997-09-16 | 2003-01-09 | Burrows Gregory G. | Recombinant MHC molecules useful for manipulation of antigen-specific T-cells |
| PT1454138E (pt) * | 2001-12-04 | 2012-03-28 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
| SG11201605632SA (en) * | 2014-01-21 | 2016-08-30 | Einstein Coll Med | Cellular platform for rapid and comprehensive t-cell immunomonitoring |
| SG10202006338UA (en) * | 2014-06-18 | 2020-08-28 | Albert Einstein College Medicine Inc | Syntac polypeptides and uses thereof |
-
2018
- 2018-09-06 IL IL297361A patent/IL297361B2/en unknown
- 2018-09-06 BR BR112020004535-7A patent/BR112020004535A2/pt unknown
- 2018-09-06 EA EA202090471A patent/EA202090471A1/ru unknown
- 2018-09-06 MX MX2020002596A patent/MX2020002596A/es unknown
- 2018-09-06 KR KR1020207008377A patent/KR20200040860A/ko not_active Ceased
- 2018-09-06 TW TW107131332A patent/TW201920248A/zh unknown
- 2018-09-06 JP JP2020503686A patent/JP2020533273A/ja active Pending
- 2018-09-06 CA CA3070484A patent/CA3070484A1/en active Pending
- 2018-09-06 IL IL272085A patent/IL272085B2/en unknown
- 2018-09-06 CN CN201880057027.0A patent/CN111050793A/zh active Pending
- 2018-09-06 EP EP18853880.5A patent/EP3678691A4/en active Pending
- 2018-09-06 WO PCT/US2018/049756 patent/WO2019051091A1/en not_active Ceased
- 2018-09-06 AU AU2018328280A patent/AU2018328280B2/en active Active
-
2020
- 2020-01-21 US US16/747,988 patent/US20200148744A1/en not_active Abandoned
-
2021
- 2021-08-24 US US17/410,453 patent/US20220119483A1/en not_active Abandoned
-
2023
- 2023-01-24 US US18/100,732 patent/US20240025964A1/en not_active Abandoned
-
2024
- 2024-05-02 US US18/653,683 patent/US20250002556A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018328280B2 (en) | 2025-02-20 |
| CA3070484A1 (en) | 2019-03-14 |
| EP3678691A1 (en) | 2020-07-15 |
| US20200148744A1 (en) | 2020-05-14 |
| IL297361B2 (en) | 2024-07-01 |
| US20220119483A1 (en) | 2022-04-21 |
| MX2020002596A (es) | 2020-07-20 |
| CN111050793A (zh) | 2020-04-21 |
| KR20200040860A (ko) | 2020-04-20 |
| US20250002556A1 (en) | 2025-01-02 |
| US20240025964A1 (en) | 2024-01-25 |
| JP2020533273A (ja) | 2020-11-19 |
| IL297361A (en) | 2022-12-01 |
| IL297361B1 (en) | 2024-03-01 |
| TW201920248A (zh) | 2019-06-01 |
| IL272085B (en) | 2022-11-01 |
| AU2018328280A1 (en) | 2020-02-13 |
| IL272085B2 (en) | 2023-03-01 |
| WO2019051091A1 (en) | 2019-03-14 |
| BR112020004535A2 (pt) | 2020-09-08 |
| EP3678691A4 (en) | 2021-06-09 |
| IL272085A (en) | 2020-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202090471A1 (ru) | Модулирующие т-клетки мультимерные полипептиды и способы их применения | |
| PH12019500782A1 (en) | Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments | |
| MY205933A (en) | Sirp-alpha binding proteins and methods of use thereof | |
| IL278091A (en) | Heterodimeric 1-PD-targeted OH-FC proteins containing OH-IL-15/IL-15Rα FC proteins and 1-PD antigen binding regions and uses thereof | |
| CY1122494T1 (el) | Πρωτεϊνες συντηξης οι οποιες περιλαμβανουν μια πρωτεϊνη δεσμευσης και ενα πολυπεπτιδιο ιντερλευκινης-15 το οποιο εχει μια μειωμενη συγγενεια για il15ra και θεραπευτικες χρησεις αυτων | |
| EA201891589A1 (ru) | Условно активные гетеродимерные полипептиды и способы их применения | |
| EA201890790A1 (ru) | Связывающие pd-1 белки и способы их применения | |
| MX2020003260A (es) | Anticuerpos asimetricos modificados que se unen al receptor fc y metodos de uso. | |
| MY206813A (en) | Multimeric t-cell modulatory polypeptides and methods of use thereof | |
| MX378451B (es) | Variantes de regiòn fc con uniòn del receptor fc neonatal (fcrn) modificado y mètodos de uso. | |
| PL3551664T3 (pl) | Przeciwciała i polipeptydy skierowane przeciwko cd127 | |
| EA201790063A1 (ru) | Слитые белки интерлейкин-2/рецептор интерлейкина-2 альфа и способы применения | |
| MX382518B (es) | Antigenos de citomegalovirus y su uso. | |
| EP3737742A4 (en) | EFFECTIVE DIVERSION OF STABLE PLURIPOTENT EMBRYONARY STEM CELLS FROM CATTLE | |
| EA201691811A1 (ru) | Варианты гфпд и способы их применения | |
| EA201791918A1 (ru) | Модификация белков клеток-хозяев | |
| MX2021007479A (es) | Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos. | |
| IL290910A (en) | Modified tff2 polypeptides containing compositions and methods of use thereof | |
| BR112016025450A2 (pt) | moduladores de canais de íons e usos dos mesmos | |
| EA201691532A1 (ru) | Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков | |
| NZ731491A (en) | Cd83 binding proteins and uses thereof | |
| EP2533811A4 (en) | MULTIMETER PROTEINS WITH IMMUNE LOBULIN CONSTANTS DOMAINS | |
| EP4450083A3 (en) | H3.3 ctl peptides and uses thereof | |
| PH12017500430A1 (en) | Solubilized enzyme and uses thereof | |
| EP3677280A4 (en) | POLYPEPTIDE AND ANTIBODIES LINKED TO A POLYPEPTIDE |